| Name | Title | Contact Details |
|---|
Mccrone Group Inc is a Westmont, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Erfa Canada Inc is a Westmount, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Fundamentally we exist for one reason: To be the trusted solution for our clients as they strive to build a better working world and improve the human experience. We are 550+ global experts that bring top-tier expertise to every stage of a project, from creating comprehensive, detailed project plans to eliminating that last punch list item and beyond, into rigorous asset management, reliability, and sustainability activities. We are your choice regardless of your location. We can support you in the US, Singapore, China, Australia, Europe, Korea, Malaysia, Vietnam and beyond. Philosophically and practically, we believe that quality, cost, and schedule can be mutually reinforcing – trade-offs are not necessary. Short-changing the focus on quality usually means problems down the road – problems that can cost money and delay the schedule. But if quality is built in from the start, then both project delivery and operational efficiency can be achieved with a much higher degree of assurance. When your project requires planned, managed, and documented high quality to exacting global standards. When you need high-performance teams on mission-critical projects. When your project is complex, high-visibility, and carries significant risk. We can help you meet a higher standard.
ZO® Skin Health provides a comprehensive range of solutions that will restore skin to a healthy state. From correcting sun damage and pigmentation to acne and aging, ZO® offers a simple, systematic approach to creating and maintaining healthy skin.
Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is focusing on the development of the lead product candidate melflufen, a first-in-class anti-cancer peptide-drug conjugate that rapidly delivers an alkylating payload into tumor cells. Melflufen is in development as a new treatment for the hematological cancer multiple myeloma and is currently being evaluated in multiple clinical studies including the pivotal phase 2 HORIZON study and the ongoing phase 3 OCEAN study. Oncopeptides` headquarters is in Stockholm, Sweden with U.S. headquarters in Boston, Mass. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.